Portfolio company CogRX gains patent coverage in Japan and China for Elayta, Cognition’s lead drug for treatment of mild to moderate Alzheimer’s disease.
Portfolio company CogRX gains patent coverage in Japan and China for Elayta, Cognition’s lead drug for treatment of mild to moderate Alzheimer’s disease.